<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In vitro and epidemiologic studies favor the efficacy of <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) in preventing skin squamous photocarcinogenesis, but there has been relatively little study of their efficacy in preventing the more common skin <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>) <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We first compared the relative anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> effects of genetic deletion and <z:chebi fb="1" ids="35475">NSAID</z:chebi> pharmacologic inhibition of cyclooxygenase (COX) enzymes in the skin of Ptch1(+/-) mice </plain></SENT>
<SENT sid="2" pm="."><plain>We then assessed the effects of <z:chebi fb="0" ids="41423">celecoxib</z:chebi> on the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> in a 3-year, double-blinded, randomized clinical trial in 60 (PTCH1(+/-)) patients with the <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>In Ptch1(+/-) mice, genetic deletion of COX1 or COX2 robustly decreased (75%; P &lt; 0.05) microscopic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, but pharmacologic inhibition with <z:chebi fb="0" ids="41423">celecoxib</z:chebi> reduced microscopic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> less efficaciously (35%; P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>In the human trial, we detected a trend for oral <z:chebi fb="0" ids="41423">celecoxib</z:chebi> reducing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> burden in <z:hpo ids='HP_0000001'>all</z:hpo> subjects (P = 0.069) </plain></SENT>
<SENT sid="5" pm="."><plain>Considering only the 60% of patients with less severe disease (&lt;15 BCCs at study entry), <z:chebi fb="0" ids="41423">celecoxib</z:chebi> significantly reduced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> number and burden: subjects receiving placebo had a 50% increase in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> burden per year, whereas subjects in the <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group had a 20% increase (P(difference) = 0.024) </plain></SENT>
<SENT sid="6" pm="."><plain>Oral <z:chebi fb="0" ids="41423">celecoxib</z:chebi> treatment inhibited <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in PTCH1(+/-) mice and had a significant anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> effect in humans with less severe disease </plain></SENT>
</text></document>